NeoTherapeutics Posts Smaller Loss for Quarter
Irvine biopharmaceutical company NeoTherapeutics Inc. narrowed its fourth-quarter loss to $9.7 million, or 48 cents a share, from $11.2 million, or 88 cents a share, a year ago. The development-stage firm posted revenue of $24,445, compared with no revenue a year earlier.
NeoTherapeutics said in a separate press release that its pre-clinical studies on two anti-psychotic drug candidates have shown positive effects in treating animal models of schizophrenia. NeoTherapeutics is seeking pharmaceutical partners to accelerate the further development.
More to Read
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
